Novartis Feed

	Est. tid*
2027-02-01	N/A	Bokslutskommuniké 2026
2026-10-26	07:00	Kvartalsrapport 2026-Q3
2026-07-16	07:00	Kvartalsrapport 2026-Q2
2026-04-24	07:00	Kvartalsrapport 2026-Q1
2026-03-10	-	X-dag ordinarie utdelning NOVN 3.70 CHF
2026-03-06	-	Årsstämma
2026-02-04	-	Bokslutskommuniké 2025
2025-10-28	-	Kvartalsrapport 2025-Q3
2025-07-17	-	Kvartalsrapport 2025-Q2
2025-04-29	-	Kvartalsrapport 2025-Q1
2025-03-11	-	X-dag ordinarie utdelning NOVN 3.50 CHF
2025-03-07	-	Årsstämma
2025-01-31	-	Bokslutskommuniké 2024
2024-10-29	-	Kvartalsrapport 2024-Q3
2024-07-18	-	Kvartalsrapport 2024-Q2
2024-04-23	-	Kvartalsrapport 2024-Q1
2024-03-07	-	X-dag ordinarie utdelning NOVN 3.30 CHF
2024-03-05	-	Årsstämma
2024-01-31	-	Bokslutskommuniké 2023
2023-10-24	-	Kvartalsrapport 2023-Q3
2023-09-15	-	Extra Bolagsstämma
2023-07-18	-	Kvartalsrapport 2023-Q2
2023-05-07	-	Årsstämma
2023-04-25	-	Kvartalsrapport 2023-Q1
2023-03-09	-	X-dag ordinarie utdelning NOVN 3.20 CHF
2023-03-07	-	Årsstämma
2023-02-01	-	Bokslutskommuniké 2022
2022-10-25	-	Kvartalsrapport 2022-Q3
2022-07-19	-	Kvartalsrapport 2022-Q2
2022-04-26	-	Kvartalsrapport 2022-Q1
2022-03-08	-	X-dag ordinarie utdelning NOVN 3.10 CHF
2022-03-04	-	Årsstämma
2022-02-02	-	Bokslutskommuniké 2021
2021-10-26	-	Kvartalsrapport 2021-Q3
2021-07-21	-	Kvartalsrapport 2021-Q2
2021-04-27	-	Kvartalsrapport 2021-Q1
2021-03-04	-	X-dag ordinarie utdelning NOVN 3.00 CHF
2021-03-02	-	Årsstämma
2021-01-26	-	Bokslutskommuniké 2020
2020-10-27	-	Kvartalsrapport 2020-Q3
2020-07-21	-	Kvartalsrapport 2020-Q2
2020-04-28	-	Kvartalsrapport 2020-Q1
2020-03-03	-	X-dag ordinarie utdelning NOVN 2.95 CHF
2020-02-28	-	Årsstämma
2020-01-29	-	Bokslutskommuniké 2019
2019-10-22	-	Kvartalsrapport 2019-Q3
2019-07-18	-	Kvartalsrapport 2019-Q2
2019-04-24	-	Kvartalsrapport 2019-Q1

Land	Schweiz
Sektor	Hälsovård
Industri	Läkemedel & Handel

2026-03-29 07:15:00 Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%

2026-03-27 07:00:00 Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation 118,98 CHF | -0,32%

2026-03-23 07:15:00 Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

2026-03-20 07:00:00 Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline 115,46 CHF | -1,47%

2026-03-13 18:35:34 Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

2026-03-06 14:24:45 Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting 123,18 CHF | -1,17%

2026-03-06 14:24:45 Aktionäre von Novartis heissen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats gut 123,18 CHF | -1,17%

2026-02-27 15:00:00 Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy 130,90 CHF | +2,67%

2026-02-27 12:29:02 Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU) 130,90 CHF | +2,67%

2026-02-24 13:15:00 New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer 129,20 CHF | +1,06%

2026-02-23 07:15:00 Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU) 127,84 CHF | +1,30%

2026-02-18 07:15:00 Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU) 127,93 CHF | -0,51%

2026-02-13 07:15:00 Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy 125,24 CHF | +1,21%

2026-02-06 18:00:00 Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

2026-02-04 07:00:00 Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im hohen einstelligen Prozentbereich, eine Kerngewinnmarge von 40% sowie weitere Fortschritte in der Pipeline 118,99 CHF | +1,97%

2026-02-04 07:00:00 Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025 118,99 CHF | +1,97%

2026-01-16 18:00:00 Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

2026-01-09 16:30:00 Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment 113,82 CHF | +0,04%

2025-12-19 20:30:21 Novartis and US government reach agreement on lowering drug prices in the US

2025-12-12 13:00:00 Novartis breaks ground on flagship manufacturing hub in North Carolina 105,31 CHF | -0,69%

2025-12-09 13:30:00 Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses 106,86 CHF | +0,26%

2025-12-09 13:15:00 1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years 106,86 CHF | +0,26%

2025-11-25 07:15:00 Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS 104,83 CHF | +1,38%

2025-11-24 23:16:48 Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA) 104,83 CHF | +1,38%

2025-11-20 07:00:00 Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets 100,30 CHF | -1,91%

2025-11-19 18:30:00 Novartis announces plans to build flagship manufacturing hub in North Carolina 100,30 CHF | -1,91%

2025-11-12 23:00:00 Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance 105,92 CHF | +1,08%

2025-11-10 15:30:00 Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan 102,20 CHF | +0,33%

2025-11-04 07:15:00 New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline 101,30 CHF | +1,59%

2025-10-29 15:30:00 Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials 98,02 CHF | -0,68%

2025-10-28 14:52:48 Novartis completes acquisition of Tourmaline Bio 98,69 CHF | -4,29%

2025-10-28 07:25:00 Novartis announces expiration of Tourmaline Bio tender offer 98,69 CHF | -4,29%

2025-10-28 07:00:00 Novartis verzeichnet im dritten Quartal solide Steigerungen beim Umsatz und operativen Kernergebnis sowie starke Fortschritte in der Pipeline; Prognose für das Geschäftsjahr 2025 bestätigt 98,69 CHF | -4,29%

2025-10-28 07:00:00 Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance 98,69 CHF | -4,29%

2025-10-26 18:00:00 Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline 103,11 CHF | -1,07%

2025-10-25 17:00:00 Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases

2025-10-22 07:15:00 Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR) 105,25 CHF | +0,62%

2025-10-22 07:00:00 Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer 105,25 CHF | +0,62%

2025-10-19 16:30:00 PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer

2025-10-17 14:00:00 Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population 103,99 CHF | -0,17%

2025-10-17 12:37:19 Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML 103,99 CHF | -0,17%

2025-10-16 07:15:00 Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN) 104,17 CHF | +0,47%

2025-09-30 22:15:00 Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) 103,98 CHF | +3,90%

2025-09-29 14:15:00 Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US 99,24 CHF | +0,92%

2025-09-29 13:44:49 Novartis announces commencement of tender offer to acquire Tourmaline Bio 99,24 CHF | +0,92%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Novartis

Kalender

Beskrivning

Vem äger bolaget?

Novartis

Kalender

Beskrivning

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden